Use of antihypertensive drugs and risk of cutaneous melanoma: a nationwide nested case-control study
Authors
Ghiasvand, R.Berge, L. A. M.
Andreassen, B. K.
Stenehjem, J. S.
Heir, T.
Karlstad, Ø.
Juzeniene, A.
Larsen, I. K.
Green, Adèle C
Veierød, M. B.
Robsahm, T. E.
Affiliation
Department of Research, Cancer Registry of Norway, Oslo, NorwayIssue Date
2022
Metadata
Show full item recordAbstract
Background: Most antihypertensives can induce dermal photosensitivity, which may increase melanoma risk. However, corroborating evidence is limited. We examined the associations between use of antihypertensives and melanoma risk. Methods: A nationwide nested case-control study was conducted using data from the Cancer Registry of Norway, the National Registry and the Norwegian Prescription Database in 2004-15. Ten controls were randomly selected for each melanoma case, matched on sex and birth year. The study included 12 048 cases and 117 895 controls. We estimated rate ratios (RRs) with 95% confidence intervals (CIs). All analyses were adjusted for ambient ultraviolet radiation (UVR). We additionally performed active comparator analyses, and sensitivity analyses by only including new users, distinguishing between exclusive and mixed users, allowing for different latency periods, and subgroup analyses by melanoma subtype and clinical stage. Results: Compared with non-use, we observed a slightly increased melanoma risk in users of diuretics (RR 1.08, CI 1.01-1.15), calcium-channel blockers (RR 1.10, CI 1.04-1.18) and drugs affecting the renin-angiotensin system (RR 1.10, CI 1.04-1.16), but not for beta blockers (RR 0.97, CI 0.92-1.03). We found no heterogeneity of associations by melanoma subtype or clinical stage and no dose-response relationship between the cumulative defined daily doses (DDDs) and melanoma. No interaction was found between cumulative DDDs and ambient UVR. Conclusions: Weak associations, with lack of a dose-response relationship and lack of interactions with ambient UVR, in the DDD analysis in this nationwide study do not support a causal relationship between antihypertensives and melanoma risk.Citation
Ghiasvand R, Berge LAM, Andreassen BK, Stenehjem JS, Heir T, Karlstad Ø, et al. Use of antihypertensive drugs and risk of cutaneous melanoma: a nationwide nested case-control study. Int J Epidemiol. 2022 Nov 22. PubMed PMID: 36413027. Epub 2022/11/23. eng.Journal
International Journal of EpidemiologyDOI
10.1093/ije/dyac223PubMed ID
36413027Additional Links
https://dx.doi.org/10.1093/ije/dyac223Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/ije/dyac223
Scopus Count
Collections
Related articles
- Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case-Control Study.
- Authors: Berge LAM, Andreassen BK, Stenehjem JS, Heir T, Karlstad Ø, Juzeniene A, Ghiasvand R, Larsen IK, Green AC, Veierød MB, Robsahm TE
- Issue date: 2020
- Reproductive factors, hormone use, and incidence of melanoma in a cohort of US Radiologic Technologists.
- Authors: Mai JZ, Zhang R, Sargen MR, Little MP, Alexander BH, Tucker MA, Kitahara CM, Cahoon EK
- Issue date: 2022 May 3
- Use of Antidepressants and Risk of Cutaneous Melanoma: A Prospective Registry-Based Case-Control Study.
- Authors: Berge LAM, Andreassen BK, Stenehjem JS, Heir T, Furu K, Juzeniene A, Roscher I, Larsen IK, Green AC, Veierød MB, Robsahm TE
- Issue date: 2020
- Association between antihypertensive medications and risk of skin cancer in people older than 65 years: a population-based study.
- Authors: Drucker AM, Hollestein L, Na Y, Weinstock MA, Li WQ, Abdel-Qadir H, Chan AW
- Issue date: 2021 Apr 12
- Use of antihypertensive drugs and risk of skin cancer.
- Authors: Schmidt SA, Schmidt M, Mehnert F, Lemeshow S, Sørensen HT
- Issue date: 2015 Aug